Clinical Trial Detail

NCT ID NCT03332797
Title A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer
Recruitment Recruiting
Gender female
Phase Phase I
Variant Requirements yes
Sponsors Genentech, Inc.
Indications

Her2-receptor negative breast cancer

Therapies

GDC-9545 + Palbociclib

GDC-9545

Age Groups: adult senior

Additional content available in CKB BOOST